About
RapiDx is developing a self-administered rapid blood diagnostic test capable of extracting an accurate amount of blood with less pain while preventing contamination. Based on RapiDxs proprietary technology, the companys menu of rapid blood diagnostic self- and single-use tests are designed for discreet home use for an array of health conditions. RapiDx has identified the painful lancing process, along with the potential risk of contamination from exposed blood, as one of the main obstacles deterring individuals from performing rapid blood tests. In response, RapiDx has integrated the lancet, blood collection, and RDT into one affordable, completely disposable device. The company is planning to launch a series of rapid blood self-tests to be used by the growing point-of-care (POC) and homecare markets. RapiDx has completed development on its first working prototype. The company has also completed a clinical trial at Tel Aviv Medical Center, with 30 volunteers demonstrating faster blood extraction and less pain compared to the gold-standard technique performed by nurses. The results have led the company to register an FDA 510(k) patent on the novel component of its blood extraction process.
Funding history · 1 round · $1.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of Rapidx?
- Rapidx is currently inactive and ceased operations in January 2023.
- When was Rapidx founded and where is its headquarters located?
- Rapidx was founded in January 2008 and is headquartered in Tel Aviv-Yafo, Israel.
- What was Rapidx's primary product focus?
- Rapidx was developing a self-administered rapid blood diagnostic test designed for discreet home use, integrating the lancet, blood collection, and rapid diagnostic test into a single disposable device.
- What was the total amount of funding raised by Rapidx?
- Rapidx raised a total of $1,000,000 in funding. For a full financing history, please refer to startupim.
- Which investors participated in Rapidx's seed round?
- In July 2008, Rapidx raised $1,000,000 in a Seed round with participation from Medvest and TechnoPlus Ventures.
- Did Rapidx conduct any clinical trials for its technology?
- Yes, Rapidx completed a clinical trial at Tel Aviv Medical Center with 30 volunteers, which demonstrated faster blood extraction and less pain compared to standard techniques.
- Has Rapidx registered any patents for its technology?
- Yes, Rapidx registered an FDA 510(k) patent for the novel component of its blood extraction process following the results of its clinical trial.
- How many employees did Rapidx have?
- Rapidx had between 1 and 10 employees, with an exact count of 6.
- Was Rapidx supported by the Israel Innovation Authority (IIA)?
- Yes, Rapidx received a grant from the IIA.